[The therapeutic effect of parlodel in the polycystic ovary syndrome].
Parlodel (2.5-50 mg/day) has been given for 1 to 7 days to 33 patients with the polycystic ovary syndrome (POS). The ovulatory menstrual cycle returned in 10 (30%) patients and 4 of them conceived. Pretreatment cycle disturbance persisted in 6 (18%) patients. Parlodel reduced mid-follicular mean blood LH levels to values of normal women. Some decrease in blood testosterone levels occurred only in the second phase of the cycle. Estradiol test in 6 patients showed normal positive and negative feedbacks in the hypothalamic-pituitary-ovarian axis. Parlodel treatment reduced basal and estradiol stimulated pituitary gonadotropin secretion. It is suggested that parlodel may be used in ovulation induction in a proportion of POS patients.
Soboleva
E L
EL
Komarov
E K
EK
Potin
V V
VV
Svechnikova
F A
FA
D000293:Adolescent; D000328:Adult; D001971:Bromocriptine / Q000627:therapeutic use*; D004341:Drug Evaluation; D004958:Estradiol / Q000097:blood; D005260:Female; D006065:Gonadotropins, Pituitary / Q000097:blood; D006801:Humans; D008599:Menstruation Disturbances / Q000097:blood / Q000188:drug therapy / Q000209:etiology; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D011374:Progesterone / Q000097:blood; D011863:Radioimmunoassay; D013739:Testosterone / Q000097:blood
D006065:Gonadotropins, Pituitary; D001971:Bromocriptine; D013739:Testosterone; D011374:Progesterone; D004958:Estradiol
Lechebnyĭ éffekt parlodela pri sindrome polikistoznykh iaichnikov.